Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

(2016) Vidmantas Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model

(2015) Seyedmojtaba Seyedmousavi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Isavuconazole in a DynamicIn VitroModel of Invasive Pulmonary Aspergillosis

(2015) Helen Box et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole (BAL4815) Pharmacodynamic Target Determination in anIn VivoMurine Model of Invasive Pulmonary Aspergillosis against Wild-Type andcyp51Mutant Isolates of Aspergillus fumigatus

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

(2013) John H Rex et al.   LANCET INFECTIOUS DISEASES

Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience

(2013) D. Neofytos et al.   Transplant Infectious Disease

Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R

(2012) Michael N. Neely et al.   THERAPEUTIC DRUG MONITORING

The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1->3)- -D-Glucan, and Consequences of Delayed Antifungal Therapy

(2010) W. W. Hope et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY